vmireavizВестник медицинского института «РЕАВИЗ». Реабилитация, Врач и ЗдоровьеBulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)2226-762X2782-1579РЕАВИЗ10.20340/vmi-rvz.2023.2.CLIN.2vmireaviz-634Research ArticleКлиническая медицинаClinical medicineБотулинотерапия при хронической мигрениBotulin therapy for chronic migrainehttps://orcid.org/0000-0002-1004-7000ИстоминаЕ. В.IstominaE. V.

Истомина Елена Вячеславовна, канд. мед. наук, доцент кафедры клинической медицины,

107564, Москва, Краснобогатырская, 2, стр. 2

Elena V. Istomina, Cand. Sci. (Med.), Associate Professor, Department of Clinical Medicine,

2, p. 2 Krasnobogatyrskaya, Moscow, 107564

IstominaReaviz@yandex.ruhttps://orcid.org/0000-0002-4717-0125ГруздеваН. И.GruzdevaN. I.

Груздева Наталья Игоревна, студентка 6 курса,

107564, Москва, Краснобогатырская, 2, стр. 2

Natal'ya I. Gruzdeva, 6th year student,

2, p. 2 Krasnobogatyrskaya, Moscow, 107564

natalegruzdeva@gmail.comМосковский медицинский университет «Реавиз»РоссияMoscow Medical University "Reaviz"Russian Federation2023060220231324044Copyright © Истомина Е.В., Груздева Н.И., 20232023Истомина Е.В., Груздева Н.И.Istomina E.V., Gruzdeva N.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestnik.reaviz.ru/jour/article/view/634

В данной статье представлен обзор актуальных современных исследований применения ботулинотерапии для профилактики и лечения пациентов с хронической мигренью, а также кратко изложены современные представления о патогенезе мигрени, её влиянии на качество жизни и трудоспособность пациентов. В настоящий момент ботулинический токсин А относится к препаратам первой группы выбора для лечения хронической мигрени. Многочисленные исследования подтверждают эффективность и безопасность его применения в клинической практике. 

This article presents a review of current modern research on the use of botulinum toxin therapy for the prevention and treatment of patients with chronic migraine, as well as briefly outlines current views on the pathogenesis of migraine, its impact on quality of life and patients' ability to work. Botulinum toxin A is currently the drug of first choice for the treatment of chronic migraine. Numerous studies confirm the effectiveness and safety of its use in clinical practice. 

мигреньхроническая мигреньголовная больтрудоспособностьботулинический токсин типа Аmigrainechronic migraineheadacheworking abilitybotulinum toxin type AReferencesВсероссийское общество неврологов. Межрегиональная общественная организация «Российское общество по изучению головной боли». Мигрень. Клинические рекомендации.МЗ РФ, Москва,2021.Ссылка активна на 18.01.2023. https://cr.minzdrav.gov.ru/schema/295_21 Vserossijskoe obshhestvo nevrologov. Mezhregional`naya obshhestvennaya organizacziya "Rossijskoe obshhestvo po izucheniyu golovnoj boli". Migren`. Klinicheskie rekomendaczii.MZ RF, Moskva, 2021.Accessed January 18,2023. (In Russ) https://cr.minzdrav.gov.ru/schema/295_2Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018;58 Suppl 1:4–16. https://doi.org/10.1111/head.133002 Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018;58 Suppl 1:4–16. https://doi.org/10.1111/head.13300Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394–402. https://doi.org/10.1111/j.1468-2982.2007.01303.x3 Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394–402. https://doi.org/10.1111/j.1468-2982.2007.01303.xCarvalho GF, Luedtke K, Braun T. Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire. J Headache Pain. 2021;22(1):126. Published 2021 Oct 21. https://doi.org/10.1186/s10194-021-01339-y4 Carvalho GF, Luedtke K, Braun T. Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire. J Headache Pain. 2021;22(1):126. Published 2021 Oct 21. https://doi.org/10.1186/s10194-021-01339-yChia V, Bogdanov A, Yusuf A, Kallenbach L. Characteristics of migraine patients with Migraine Disability Assessment (MIDAS) scores in real-world clinical practice. Cephalalgia Reports. 2020;3. https://doi.org/10.1177/25158163209284635 Chia V, Bogdanov A, Yusuf A, Kallenbach L. Characteristics of migraine patients with Migraine Disability Assessment (MIDAS) scores in real-world clinical practice. Cephalalgia Reports. 2020;3. https://doi.org/10.1177/2515816320928463Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29. Published 2021 Apr 21. https://doi.org/10.1186/s10194-021-01243-56 Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29. Published 2021 Apr 21. https://doi.org/10.1186/s10194-021-01243-5Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92. Published 2019 Aug 30. https://doi.org/10.1007/s11916-015-0521-07 Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92. Published 2019 Aug 30. https://doi.org/10.1007/s11916-015-0521-0Дубенко О.Е. Головная боль при медикаментозной передозировке: клинические и диагностические аспекты. Международный неврологический журнал. 2021;16(2):45-51. https://doi.org/10.22141/2224-0713.16.2.2020.2009628 Dubenko OY. Medication overuse headache: clinical and diagnostic aspects. International Neurological Journal. 2021;16(2):45–51. (In Russ). https://doi.org/10.22141/2224-0713.16.2.2020.200962Дельва М.Ю., Никифирова Е.С. Хроническая мигрень: современные принципы менеджмента (обзор литературы). Международный неврологический журнал. 2022;(2.80):126–132. https://doi.org/10.22141/2224-0713.2.80.2016.740199 Delva MY, Nikiforova OS. Chronic Migraine: Current Principles of Management (Literature Review). International Neurological Journal. 2022;(2.80):126–132. (In Russ). https://doi.org/10.22141/2224-0713.2.80.2016.74019Castrillo Sanz A, Morollón Sánchez-Mateos N, Simonet Hernández C, et al. Experience with botulinum toxin in chronic migraine. Experiencia con toxina botulínica en la migraña crónica. Neurologia (Engl Ed). 2018;33(8):499–504. https://doi.org/10.1016/j.nrleng.2016.09.00110 Castrillo Sanz A, Morollón Sánchez-Mateos N, Simonet Hernández C, et al. Experience with botulinum toxin in chronic migraine. Experiencia con toxina botulínica en la migraña crónica. Neurologia (Engl Ed). 2018;33(8):499–504. https://doi.org/10.1016/j.nrleng.2016.09.001Rothrock JF, Adams AM, Lipton RB, et al. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Headache. 2019;59(10):1700–1713. https://doi.org/10.1111/head.1365311 Rothrock JF, Adams AM, Lipton RB, et al. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Headache. 2019;59(10):1700–1713. https://doi.org/10.1111/head.13653Ion I, Renard D, Le Floch A, et al. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine. Toxins (Basel). 2018;10(6):221. Published 2018 Jun 1. https://doi.org/10.3390/toxins1006022112 Ion I, Renard D, Le Floch A, et al. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine. Toxins (Basel). 2018;10(6):221. Published 2018 Jun 1. https://doi.org/10.3390/toxins10060221

The authors declare that there are no conflicts of interest present.